The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Advances in pyruvate kinase activators for MDS and PKD: mitapivat & AG946
Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, highlights recent developments in pyruvate kinase activators to treat pyruvate kinase deficiency (PKD) and diseases of hemolysis and ineffective erythropoiesis including myelodysplastic syndromes (MDS), commenting on mitapivat and AG946. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Argenx: Consultancy; Novartis: Consultancy; Moderna: Consultancy; Dova: Consultancy, Research Funding; Forma: Consultancy; Rigel: Consultancy; Amgen: Research Funding; Sobi: Consultancy, Research Funding; Agios: Consultancy, Research Funding.
